Report #2898297

Received May 29, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 72 yrs
State: CA
Recovered: Unknown
Vaccinated: May 21, 2026
Onset: May 21, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPAB	HEP A + HEP B (TWINRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	F95HB	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 72-year-old male patient who received HAB (Twinrix) suspension for injection in pre-filled syringe (batch number F95HB with expiry date 29-MAY-2028) for prophylaxis. Previously administered products included Twinrix (received first dose on 24-DEC-2025 without batch number and expiry date). On 21-MAY-2026, the patient received the 2nd dose of Twinrix. On 21-MAY-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 22-MAY-2026 The patient received a 2nd dose late.